 |
市场调查报告书
商品编码
1616769
门诊肿瘤输液市场机会、成长动力、产业趋势分析及 2024 年至 2032 年预测Outpatient Oncology Infusion Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032 |
||||||
2023 年，全球门诊肿瘤输液市场估值为24 亿美元。病率上升推动的，以及更广泛的医疗保健政策和保险范围。这种动态促进了向门诊治疗的过渡，因其成本效益和效率而受到称讚。癌症仍然是一个紧迫的全球公共卫生挑战，病例和死亡率的上升凸显了这个挑战。例如，美国癌症协会报告称，2021 年美国约有 608,570 例癌症相关死亡。
这种巨大的癌症负担扩大了对输注疗法和药物输注系统的需求，推动了市场成长。几个关键趋势正在塑造市场轨迹。这些包括不断增长的老年人口以及在舒适性、成本效益和技术创新的推动下向门诊设施的明显转变。此外，不断发展的医疗保健政策和不断上升的生存率将在预测期内提振市场。
整个产业分为产品、应用、疗法、模式、区域。市面上的产品分为输液帮浦、静脉注射器、静脉插管和无针连接器。输液帮浦领域处于领先地位，2023 年收入达 12 亿美元。输液帮浦确保化疗药物的连续、受控输送，最大限度地减少剂量错误并增强治疗效果。
| 市场范围 | |
|---|---|
| 开始年份 | 2023年 |
| 预测年份 | 2024-2032 |
| 起始值 | 24亿美元 |
| 预测值 | 59 亿美元 |
| 复合年增长率 | 10.6% |
门诊肿瘤输液市场的应用涵盖肺癌、肝癌、乳癌、摄护腺癌等。 2023 年，乳癌以 20.5% 的市占率领先。这种主导地位源于其全球流行、一系列先进的治疗途径、对门诊护理的倾斜以及强大的患者支持机制。值得注意的是，《2022 年全球癌症统计》强调2022 年将新增230 万名女性乳癌病例。 10%。公共卫生措施、筛检进步和诊断技术进步在促进及时的癌症干预和治疗方面进一步发挥了作用。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 输液帮浦的最新技术进步
- 全球癌症盛行率上升
- 政府提高癌症意识的措施不断涌现
- 产业陷阱与挑战
- 癌症治疗费用高昂
- 成长动力
- 成长潜力分析
- 监管环境
- 技术景观
- 报销场景
- 波特的分析
- PESTEL分析
- 未来市场趋势
- 差距分析
第 4 章：竞争格局
- 介绍
- 公司矩阵分析
- 公司市占率分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按产品分类，2021 - 2032 年
- 主要趋势
- 点滴帮浦
- 静脉注射套
- 静脉插管
- 无针头连接器
第 6 章：市场估计与预测：按应用分类，2021 - 2032
- 主要趋势
- 肺癌
- 肝癌
- 乳癌
- 摄护腺癌
- 其他癌症
第 7 章：市场估计与预测：按疗法分类，2021 - 2032 年
- 主要趋势
- 化疗
- 标靶治疗
- 免疫疗法
- 荷尔蒙疗法
第 8 章：市场估计与预测：按模式，2021 - 2032
- 主要趋势
- 肌肉注射 (IM)
- 静脉注射 (IV)
- 皮下
- 其他模式
第 9 章：市场估计与预测：按地区，2021 - 2032
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
第 10 章：公司简介
- B. Braun Melsungen AG
- Baxter
- Becton, Dickinson, and Company
- Fresenius Kabi
- ICU Medical, Inc
- IRadimed Corporation
- Medtronic PLC
- Micrel Medical Devices SA
- Moog, Inc.
- Nipro Corporation
- Roche Diagnostics
- Smiths Medical
- Teleflex, Inc.
- Terumo Corporation
The Global Outpatient Oncology Infusion Market was valued at USD 2.4 billion in 2023. Projections indicate a growth trajectory, with an expected CAGR of 10.6% from 2024 to 2032. This robust market expansion is fueled by technological strides in infusion pumps, a rising cancer prevalence, and broader healthcare policies and insurance coverage. Such dynamics bolster the transition to outpatient treatments, lauded for their cost-effectiveness and efficiency. Cancer remains a pressing global public health challenge, underscored by rising cases and mortality rates. For instance, the American Cancer Society reported approximately 608,570 cancer-related deaths in the U.S. in 2021. Breast cancer topped the list with 284,200 new cases, followed by prostate and lung cancers.
This significant cancer burden amplifies the demand for infusion therapies and drug infusion systems, propelling the market growth. Several pivotal trends are shaping the market trajectory. These encompass a growing geriatric demographic and a pronounced shift towards outpatient facilities, driven by comfort, cost-effectiveness, and technological innovations. Moreover, evolving healthcare policies and rising survival rates are poised to bolster the market during the forecast period.
The overall industry is divided into product, application, therapy, mode, and region. The market categorizes products into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. Leading the pack, the infusion pumps segment raked in USD 1.2 billion in revenue in 2023. Their rising adoption in outpatient cancer therapies is attributed to precise drug delivery, the capability to handle intricate chemotherapy regimens, and enhanced patient outcomes. Infusion pumps ensure continuous, controlled delivery of chemotherapeutic agents, minimizing dosage errors and amplifying treatment efficacy.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $2.4 Billion |
| Forecast Value | $5.9 Billion |
| CAGR | 10.6% |
Applications in the outpatient oncology infusion market span lung, liver, breast, prostate cancers, and others. In 2023, breast cancer led the charge with a 20.5% market share. This dominance stems from its global prevalence, a spectrum of advanced treatment avenues, a tilt towards outpatient care, and robust patient support mechanisms. Notably, Global Cancer Statistics 2022 highlighted 2.3 million new female breast cancer cases in 2022.North America, with a 2023 revenue of USD 1 billion, is set to grow at a CAGR of 10% from 2024 to 2032. The region's leadership is driven by a surge in cancer prevalence, underscoring the need for efficient treatment avenues like outpatient oncology infusions.A heightened cancer awareness, emphasizing early diagnosis, further cements North America's position. Public health initiatives, screening advancements, and diagnostic tech progress have further played roles in facilitating timely cancer interventions and treatments.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Recent technological advancements in infusion pumps
- 3.2.1.2 Rising prevalence of cancer across the globe
- 3.2.1.3 Surging government initiatives for cancer awareness
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High costs of cancer therapies
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technology landscape
- 3.6 Reimbursement scenario
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
- 3.9 Future market trends
- 3.10 Gap analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Infusion pumps
- 5.3 Intravenous sets
- 5.4 IV cannulas
- 5.5 Needleless connectors
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Lung cancer
- 6.3 Liver cancer
- 6.4 Breast cancer
- 6.5 Prostate cancer
- 6.6 Other cancers
Chapter 7 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Chemotherapy
- 7.3 Targeted therapy
- 7.4 Immunotherapy
- 7.5 Hormonal therapy
Chapter 8 Market Estimates and Forecast, By Mode, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Intramuscular (IM)
- 8.3 Intravenous (IV)
- 8.4 Subcutaneous
- 8.5 Other modes
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 B. Braun Melsungen AG
- 10.2 Baxter
- 10.3 Becton, Dickinson, and Company
- 10.4 Fresenius Kabi
- 10.5 ICU Medical, Inc
- 10.6 IRadimed Corporation
- 10.7 Medtronic PLC
- 10.8 Micrel Medical Devices SA
- 10.9 Moog, Inc.
- 10.10 Nipro Corporation
- 10.11 Roche Diagnostics
- 10.12 Smiths Medical
- 10.13 Teleflex, Inc.
- 10.14 Terumo Corporation
